AbbVie has recently acquired a biotech firm based in Wisconsin for $200 million, as part of its ongoing strategy to expand through acquisitions.
The target company was previously a spin-off from Roche, indicating AbbVie's commitment to growing its presence in the biopharmaceutical sector.
This acquisition is in line with AbbVie's focus on strengthening its capabilities and offerings in the healthcare market. It also reflects the industry-wide trend of consolidation as companies aim to capitalize on innovative technologies and therapies for growth.